Roche Exit Strengthens Pfizer And Merck & Co In Covid Pill Market
US Stockpiling Could See Pfizer Earn $15bn-25bn
Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.
Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.